## https://www.asahi.com/articles/ASR747RQRR6ZULBH003.html?iref=comtop_Tech_science_04; last accessed: 20230706

> AIが薬の成分を「生成」、難病患者に治験開始　コスト10分の1に

AI "auto-generates" the composition of medical drugs, the beginning of treatment-tests for patients with difficult cases, COSTS DOWN by 1/10


> 竹野内崇宏

TAKENOUCHI, Takahiro 

> 2023年7月5日 18時00分

2023-07-05T18:00

> 生成AI（人工知能）を使って新薬候補を開発し、難病の患者に投与する臨床試験が始まった。

New medical drugs are being developed using AI (Artificial Intelligence) automation, and bed-side tests with patients who have difficult cases have begun. 

> 米ニューヨークと香港を拠点とする「インシリコ・メディシン社」が6月27日、発表した。同社によれば生成AIによって新薬候補を見つけて患者への投与に進んだのは世界で初めてという。AIを使うことで費用や時間を格段に抑えることができたとしている。

Based in NEW YORK and HONG-KONG, "INSILICO MEDICINE" have announced on the 27th of June, that they are the world's first in advancing patient administration using the new medical drugs discovered with AI automation. By using AI, they say that payment costs and elapsed time can be markedly managed.

>　対象となる病気は特発性肺線維症（IPF）。原因がわからないまま肺が硬くなる病気で、平均余命2～6年。進行を抑える薬しかなく、日本でも難病に指定されている。同社によれば世界での患者は約500万人にのぼる。

The Illness that is particularly targeted in this case is the Idiopathic Pulmonary Fibrosis (IPF). It is a type of illness where the lungs harden, albeit whose cause remains unknown, giving the patient an average remaining life of 2~6 years. The only medicine available is to manage the illness so that it does not further advance. In Japan, it has been classified to be a difficult illness. According to the company, the number of patients globally suffering from this illness is climbing to 5 million people.

>　そこでAI創薬に特化したインシリコ社は、IPFを治療できる薬の開発に着手。開発初期の2段階でAIを活用した。

INSILICO is specializing in AI-generated medical drugs, and have started development of drugs to treat IPF. AI is used in the 2nd stage of the initial phase of development.

>　まずは病気を引き起こす原因…

First, the reason that causes the illness...

### REFERENCE

GOOGLE SEARCH ENGINE; TRANSLATE
